Browse

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial

DC Field Value Language
dc.contributor.authorKim, Yeul Hong-
dc.contributor.authorYamaguchi, Kensei-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorTakiuchi, Hiroya-
dc.contributor.authorKang, Won Ki-
dc.contributor.authorSato, Atsushi-
dc.contributor.authorKang, Yoon-Koo-
dc.contributor.authorSakamoto, Junichi-
dc.contributor.authorAbe, Chigusa-
dc.contributor.authorSakata, Yuh-
dc.date.accessioned2010-01-11T07:26:59Z-
dc.date.available2010-01-11T07:26:59Z-
dc.date.issued2007-08-04-
dc.identifier.citationJpn J Clin Oncol. 2007 Jul;37(7):501-8. Epub 2007 Aug 2.en
dc.identifier.issn1465-3621 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17673470-
dc.identifier.urihttp://hdl.handle.net/10371/29387-
dc.description.abstractBACKGROUND: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. METHODS: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. RESULTS: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). CONCLUSIONS: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/administration & dosageen
dc.subjectAntineoplastic Agents, Phytogenic/administration & dosage/toxicityen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration &en
dc.subjectdosage/toxicityen
dc.subjectCisplatin/administration & dosageen
dc.subjectDrug Administration Scheduleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosage/toxicityen
dc.subjectStomach Neoplasms/*drug therapy/mortalityen
dc.subjectSurvival Rateen
dc.titlePhase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trialen
dc.typeArticleen
dc.contributor.AlternativeAuthor김열홍-
dc.contributor.AlternativeAuthor방영주-
dc.contributor.AlternativeAuthor강원기-
dc.contributor.AlternativeAuthor강윤구-
dc.identifier.doi10.1093/jjco/hym054-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse